Lixte and City of Hope enter agreement to study LB-100 in phase Ib study for extensive stage SCLC Jan. 20, 2021
New SIRP-alpha antibodies inducing tumor cell phagocytosis without affecting T-cell functionality Jan. 20, 2021
Gemcitabine can be repurposed as anti-HEV agent, in particular for HEV-infected cancer patients Jan. 20, 2021
Shanghai Jemincare Pharmaceuticals, Jiangxi Jemincare Group present factor XIa inhibitors Jan. 20, 2021
RSS